K.C. Aalders

825 total citations
13 papers, 305 citations indexed

About

K.C. Aalders is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, K.C. Aalders has authored 13 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 7 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in K.C. Aalders's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). K.C. Aalders is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). K.C. Aalders collaborates with scholars based in Netherlands, Belgium and Portugal. K.C. Aalders's co-authors include Konstantinos Tryfonidis, Fátima Cardoso, Elżbieta Senkus, Thijs van Dalen, Gabe S. Sonke, P. J. van Diest, Liesbeth Boersma, Margriet van der Heiden‐van der Loo, A.C.M. van Bommel and Sabine Siesling and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

K.C. Aalders

13 papers receiving 301 citations

Peers

Countries citing papers authored by K.C. Aalders

Since Specialization

Citations

This map shows the geographic impact of K.C. Aalders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.C. Aalders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.C. Aalders more than expected).

Fields of papers citing papers by K.C. Aalders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.C. Aalders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.C. Aalders. The network helps show where K.C. Aalders may publish in the future.

Co-authorship network of co-authors of K.C. Aalders

This figure shows the co-authorship network connecting the top 25 collaborators of K.C. Aalders. A scholar is included among the top collaborators of K.C. Aalders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.C. Aalders. K.C. Aalders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X 2020 ·Cancer Research ·Martine Piccart, Coralie Poncet, Fátima Cardoso, Laura van’t Veer, Suzette Delaloge, Jean‐Yves Pierga, Étienne Brain, Suzan Vrijaldenhoven, Peter A. Neijenhuis, K.C. Aalders, Emiel J. Rutgers	4
2	Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial 2020 ·European Journal of Cancer ·Otto Metzger, Fátima Cardoso, Coralie Poncet, Christine Desmedt, Sabine C. Linn, Jelle Wesseling, Florentine Hilbers, K.C. Aalders, Mauro Delorenzi, Suzette Delaloge, Jean‐Yves Pierga, Étienne Brain, Suzan Vrijaldenhoven, Peter A. Neijenhuis, Emiel J. Rutgers, Martine Piccart, Laura van ‘t Veer, Giuseppe Viale	19
3	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial 2018 ·Breast Cancer Research and Treatment ·(unknown), K.C. Aalders, Nathan Touati, Konstantinos Tryfonidis, (unknown), Saskia Litière, Jonas Bergh, (unknown), David Cameron, Hervé Bonnefoi	1
4	Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment 2018 ·Annals of Surgical Oncology ·(unknown), (unknown), K.C. Aalders, K. Schreuder, (unknown), Sabine Siesling, (unknown), Thijs van Dalen	4
5	Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial 2018 ·Annals of Oncology ·Michail Ignatiadis, Saskia Litière, Françoise Rothé, Sabine Riethdorf, Charlotte Proudhon, Tanja Fehm, K.C. Aalders, Helmut Forstbauer, Peter A. Fasching, Étienne Brain, Peter Vuylsteke, Emmanuel Guardiola, Ralf Lorenz, Klaus Pantel, Konstantinos Tryfonidis, Wolfgang Janni, Martine Piccart, Christos Sotiriou, Brigitte Rack, Jean‐Yves Pierga	55
6	Abstract OT3-07-01: Update of the randomized, non-inferiority LORD trial testing safety of active surveillance for women with screen-detected low risk ductal carcinoma in situ (EORTC-1401-BCG/BOOG 2014-04, DCIS) 2018 ·Cancer Research ·Jelle Wesseling, (unknown), Konstantinos Tryfonidis, Coralie Poncet, K.C. Aalders, (unknown), Victoria Skinner, Claudette E. Loo, (unknown), Eveline M. A. Bleiker, Valesca P. Retèl, Ruud M. Pijnappel, Nina Bijker, Emiel J. Rutgers, Frederieke van Duijnhoven	4
7	Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial 2017 ·European Journal of Cancer ·K.C. Aalders, (unknown), Marieke E. Straver, Leen Slaets, Saskia Litière, Giuseppe Viale, Laura J. van’t Veer, Annuska M. Glas, Mauro Delorenzi, Thijs van Dalen, Konstantinos Tryfonidis, Martine Piccart, Fátima Cardoso, Emiel J. Rutgers	10
8	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study 2017 ·Breast Cancer Research and Treatment ·Konstantinos Tryfonidis, Sandrine Marréaud, Hussein Khaled, B. De Valk, Jan B. Vermorken, Marzena Wełnicka-Jaśkiewicz, K.C. Aalders, John M.S. Bartlett, Laura Biganzoli, Jan Bogaerts, David Cameron, (unknown)	2
9	Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy 2017 ·Annals of Oncology ·(unknown), Coralie Poncet, Leen Slaets, Giuseppe Viale, Femke De Snoo, K.C. Aalders, Laura van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Fátima Cardoso	2
10	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives 2017 ·Cancer Treatment Reviews ·K.C. Aalders, Konstantinos Tryfonidis, Elżbieta Senkus, Fátima Cardoso	98
11	Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer 2016 ·European Journal of Cancer ·K.C. Aalders, A.C.M. van Bommel, Thijs van Dalen, Gabe S. Sonke, P. J. van Diest, Liesbeth Boersma, (unknown)	41
12	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer 2016 ·Journal of Clinical Oncology ·K.C. Aalders, Emily L. Postma, Luc J. A. Strobbe, Margriet van der Heiden‐van der Loo, Gabe S. Sonke, Liesbeth Boersma, P. J. van Diest, Sabine Siesling, Thijs van Dalen	39
13	Prognostic Significance of Tumor-Positive Internal Mammary Sentinel Lymph Nodes in Breast Cancer: A Multicenter Cohort Study 2015 ·Annals of Surgical Oncology ·Eva V. E. Madsen, K.C. Aalders, Margriet van der Heiden‐van der Loo, Paul D. Gobardhan, Pouline M. P. van Oort, (unknown), Emiel J. Rutgers, (unknown), (unknown), Thijs van Dalen	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact